#rvmd
Latest news and interesting information about rvmd.
Bernstein Starts Revolution Med at Market Perform
Bernstein initiates Revolution Medicines coverage with Market Perform rating and $151 target. Stock trades at $153.73.
Revolution Medicines Phase 3 Results Webcast
Revolution Medicines webcast on Phase 3 RASolute 302 results for daraxonrasib in pancreatic cancer. Learn more.
Revolution stock buy rating from Truist
Truist Securities gives Revolution Medicines a buy rating with a $179 price target. Daraxon's potential and company outlook.
...